BR112015029386A8 - uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit - Google Patents
uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit Download PDFInfo
- Publication number
- BR112015029386A8 BR112015029386A8 BR112015029386A BR112015029386A BR112015029386A8 BR 112015029386 A8 BR112015029386 A8 BR 112015029386A8 BR 112015029386 A BR112015029386 A BR 112015029386A BR 112015029386 A BR112015029386 A BR 112015029386A BR 112015029386 A8 BR112015029386 A8 BR 112015029386A8
- Authority
- BR
- Brazil
- Prior art keywords
- lenvatinib
- eribulin
- combination therapy
- kit
- pharmaceutical composition
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 title abstract 2
- 229960003649 eribulin Drugs 0.000 title abstract 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003784 lenvatinib Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
resumo patente de invenção: "uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer". a presente invenção refere-se aos métodos e composições para uso no tratamento de doenças associadas à proliferação celular excessiva, tal como câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361839542P | 2013-06-26 | 2013-06-26 | |
US61/839,542 | 2013-06-26 | ||
PCT/JP2014/067723 WO2014208774A1 (en) | 2013-06-26 | 2014-06-26 | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015029386A2 BR112015029386A2 (pt) | 2017-07-25 |
BR112015029386A8 true BR112015029386A8 (pt) | 2020-03-17 |
BR112015029386B1 BR112015029386B1 (pt) | 2023-11-14 |
Family
ID=51210708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015029386-7A BR112015029386B1 (pt) | 2013-06-26 | 2014-06-26 | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
Country Status (12)
Country | Link |
---|---|
US (1) | US9549922B2 (pt) |
EP (1) | EP3013335B1 (pt) |
JP (1) | JP6404242B2 (pt) |
KR (1) | KR102265952B1 (pt) |
CN (1) | CN105338977B (pt) |
AU (1) | AU2014299699B2 (pt) |
BR (1) | BR112015029386B1 (pt) |
CA (1) | CA2915005C (pt) |
ES (1) | ES2705698T3 (pt) |
IL (1) | IL242386B (pt) |
RU (1) | RU2672585C2 (pt) |
WO (1) | WO2014208774A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ595212A (en) | 2009-03-30 | 2014-02-28 | Eisai R&D Man Co Ltd | Liposome composition |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
PT3263106T (pt) | 2015-02-25 | 2024-01-12 | Eisai R&D Man Co Ltd | Método para suprimir o amargor do derivado de quinolina |
CA2978311A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating cancer |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
ES2952680T3 (es) * | 2016-04-28 | 2023-11-03 | Eisai R&D Man Co Ltd | Eribulina para inhibir el crecimiento tumoral |
CN105832732A (zh) * | 2016-05-30 | 2016-08-10 | 青岛云天生物技术有限公司 | 一种用于胃癌治疗的药物组合物及其应用 |
CN110139866B (zh) * | 2017-01-02 | 2022-05-17 | 研成精密化学株式会社 | 用于制备甲磺酸艾日布林的中间体以及制备其的方法 |
JP6581320B2 (ja) * | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
CN107973804B (zh) * | 2017-11-29 | 2020-07-03 | 戊言医药科技(上海)有限公司 | 艾瑞布林中间体的合成方法 |
MA51570A (fr) | 2018-01-10 | 2020-11-18 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du carcinome hépatocellulaire |
CN109793736A (zh) * | 2019-01-31 | 2019-05-24 | 徐州医科大学 | 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用 |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
CN114028394A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | 低剂量仑伐替尼在制备治疗肝癌的药物中的用途 |
WO2023018675A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
CA2755266C (en) | 1998-06-17 | 2014-08-12 | Eisai R&D Management Co., Ltd. | Intermediates for preparing macrocyclic analogs |
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
EP1481678A4 (en) | 2002-03-05 | 2009-12-30 | Eisai R&D Man Co Ltd | ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
SI1698623T1 (sl) | 2003-12-25 | 2015-07-31 | Eisai R&D Management Co., Ltd. | Kristal soli 4-(3-kloro -4-(ciklopropilaminokarbonil)amino-fenoksi)-7- metoksi-6-kinolinkarboksamida ali njihov solvat in postopek njune proizvodnje |
WO2005118565A1 (en) * | 2004-06-03 | 2005-12-15 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
CN101443009A (zh) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
KR20090108086A (ko) | 2007-01-19 | 2009-10-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 췌장암 치료용 조성물 |
CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
US8609640B2 (en) * | 2007-07-25 | 2013-12-17 | Eisai, Inc. | Multikinase inhibitors for use in the treatment of cancer |
WO2009046308A1 (en) | 2007-10-03 | 2009-04-09 | Eisai R & D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
WO2009096377A1 (ja) | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
SG10201500552PA (en) | 2010-01-26 | 2015-03-30 | Eisai R&D Man Co Ltd | Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
US20120077837A1 (en) | 2010-09-24 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Anti-tumor agent |
EP2680839A1 (en) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
JP2014509515A (ja) * | 2011-03-18 | 2014-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エリブリンに対する応答を予測するための方法及び組成物 |
EP2700403B1 (en) * | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
WO2012154935A1 (en) | 2011-05-12 | 2012-11-15 | Eisai R&D Management Co., Ltd. | Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof |
EP2714937B1 (en) * | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
CA2940983A1 (en) | 2014-03-03 | 2015-09-11 | Eisai R&D Management Co., Ltd. | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
BR112016026545A8 (pt) | 2014-05-28 | 2021-07-06 | Eisai R&D Man Co Ltd | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama |
EP3148336B1 (en) | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
JP6644479B2 (ja) | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとs−1(もしくは5−fu)の使用 |
-
2014
- 2014-06-26 KR KR1020167001713A patent/KR102265952B1/ko active IP Right Grant
- 2014-06-26 JP JP2015562231A patent/JP6404242B2/ja active Active
- 2014-06-26 CA CA2915005A patent/CA2915005C/en active Active
- 2014-06-26 RU RU2016102158A patent/RU2672585C2/ru active
- 2014-06-26 BR BR112015029386-7A patent/BR112015029386B1/pt active IP Right Grant
- 2014-06-26 WO PCT/JP2014/067723 patent/WO2014208774A1/en active Application Filing
- 2014-06-26 CN CN201480036218.0A patent/CN105338977B/zh active Active
- 2014-06-26 AU AU2014299699A patent/AU2014299699B2/en active Active
- 2014-06-26 ES ES14739971T patent/ES2705698T3/es active Active
- 2014-06-26 EP EP14739971.1A patent/EP3013335B1/en active Active
- 2014-06-26 US US14/315,930 patent/US9549922B2/en active Active
-
2015
- 2015-11-01 IL IL242386A patent/IL242386B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP2016528162A (ja) | 2016-09-15 |
CA2915005C (en) | 2021-12-28 |
BR112015029386B1 (pt) | 2023-11-14 |
EP3013335A1 (en) | 2016-05-04 |
CA2915005A1 (en) | 2014-12-31 |
US20150005343A1 (en) | 2015-01-01 |
CN105338977B (zh) | 2018-10-16 |
RU2672585C2 (ru) | 2018-11-16 |
CN105338977A (zh) | 2016-02-17 |
KR102265952B1 (ko) | 2021-06-16 |
AU2014299699A1 (en) | 2015-12-10 |
BR112015029386A2 (pt) | 2017-07-25 |
RU2016102158A (ru) | 2017-07-31 |
IL242386B (en) | 2019-06-30 |
WO2014208774A1 (en) | 2014-12-31 |
US9549922B2 (en) | 2017-01-24 |
ES2705698T3 (es) | 2019-03-26 |
JP6404242B2 (ja) | 2018-10-10 |
EP3013335B1 (en) | 2018-11-07 |
KR20160023816A (ko) | 2016-03-03 |
AU2014299699B2 (en) | 2019-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
GT201500248A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
ECSP12012310A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
GB201209613D0 (en) | New compounds | |
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2014, OBSERVADAS AS CONDICOES LEGAIS |